Dapagliflozin inhibits which glucose transpoer?
**Core Concept**
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which plays a crucial role in glucose reabsorption in the kidneys. SGLT2 is responsible for approximately 90% of glucose reabsorption in the proximal convoluted tubule of the nephron.
**Why the Correct Answer is Right**
Dapagliflozin works by competitively inhibiting SGLT2, thereby reducing glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, which in turn lowers blood glucose levels. The SGLT2 inhibitors act independently of insulin, making them a valuable therapeutic option for patients with type 2 diabetes.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because SGLT1 is primarily involved in glucose reabsorption in the small intestine, not the kidneys.
* **Option B:** This option is incorrect because DPP-4 inhibitors target the enzyme dipeptidyl peptidase-4, which is involved in the inactivation of incretin hormones, not glucose transport.
* **Option C:** This option is incorrect because GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, which enhances insulin secretion and glucose uptake, rather than inhibiting glucose transport.
**Clinical Pearl / High-Yield Fact**
SGLT2 inhibitors like dapagliflozin have been associated with a reduced risk of cardiovascular events, including heart failure and stroke, in patients with type 2 diabetes.
**Correct Answer: A. SGLT2**